Quince Therapeutics, Inc. expected to post a loss of $17.88 a share - Earnings Preview

IRulya Therapeutics

07/08/2026 12:01

Quince Therapeutics, Inc. QNCX.OQ QNCX.O is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Quince Therapeutics, Inc. is for a loss of $17.88 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Quince Therapeutics, Inc. is $82.00, about 177.6% above its last closing price of $29.54
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-51.20
-51.20
57.60
Beat
212.5
Dec. 31 2026
-39.55
-37.76
-1.42 hundred
Missed
-276.1
Sep. 30 2025
-41.12
-43.28
-50.00
Missed
-15.5​
Jun. 30 2025
-51.47
-50.33
-46.00
Beat
8.6
​​Mar. 31 2025
-45.14
-45.50
-68.00
Missed
-49.5
Dec. 31 2024
-36.75
-35.00
-56.00
Missed
-60​
Sep. 30 2024
-31.38
-42.00
-26.00
Beat
38.1
-1.28 hundred
This summary was machine generated August 7 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)